Influenza viruses are among the most likely triggers of future pandemics. A research team from the Helmholtz Center for Infection Research (HZI) and the Medical Center—University of Freiburg has ...

In the following Q&A, Bob Chen, VP of Discovery Systems at OmniAb, explains how the xPloration platform works and how it can be applied in antibody discovery.

Discover how omega-3 fatty acids benefit your body, from reducing inflammation to supporting brain health, and learn the most ...

Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix.

Q1 2025 Earnings Call Transcript May 13, 2025 Capricor Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinica ...

This manuscript characterizes a mutated clone of RNA polymerase I in yeast, referred to as SuperPol, to understand the mechanisms of RNA polymerase I elongation and termination. The authors present ...

At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation there ...

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

Cash, cash equivalents and short-term investments were $83.1 million as of March 31, 2025, compared to $125.7 million as of December 31, 2024. Adverum expects its cash, cash equivalents and short-term ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...